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Abstract: miR-23a, a member of the miR-23a/24-2/27a cluster, has been demonstrated to play pivotal
roles in many cellular activities. However, the mechanisms of how bta-miR-23a controls the myogenic
differentiation (MD) of PDGFRα− bovine progenitor cells (bPCs) remain poorly understood. In the
present work, bta-miR-23a expression was increased during the MD of PDGFRα− bPCs. Moreover,
bta-miR-23a overexpression significantly promoted the MD of PDGFRα− bPCs. Luciferase reporter
assays showed that the 3’-UTR region of MDFIC (MyoD family inhibitor domain containing) could
be a promising target of bta-miR-23a, which resulted in its post-transcriptional down-regulation.
Additionally, the knockdown of MDFIC by siRNA facilitated the MD of PDGFRα− bPCs, while the
overexpression of MDFIC inhibited the activating effect of bta-miR-23a during MD. Of note, MDFIC
might function through the interaction between MyoG transcription factor and MEF2C promoter. This
study reveals that bta-miR-23a can promote the MD of PDGFRα− bPCs through post-transcriptional
downregulation of MDFIC.
Keywords: bta-miR-23a; fetal muscle development; MDFIC
1. Introduction
The development of skeletal muscles can occur as early as the embryonic period [1]. During the
embryonic process, the first myogenesis wave involves the formation of primary myofibers, while the
second myogenesis wave facilitates the production of secondary myofibers that account for the majority
of skeletal muscle fibers. Considering that there is no available information on the increased number
of muscle fibers following birth, the embryo-fetal stage can be considered a great determinant of
skeletal muscle development [2–4]. Differentiation of skeletal muscles involves complex and multilevel
processes, and such complex differentiation processes are orchestrated by a variety of myogenic
regulatory factors, such as myogenic differentiation (MyoD), myogenin (MyoG), myogenic factor 5
(Myf5), and myogenic factor 6 (Myf6). MyoD and Myf5 are both transcription factors for initiating
myogenic commitment [5]. Myf6 is involved in the processes of differentiation and maturation of
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myotubes during embryogenesis [6]. MyoG is essential for the terminal differentiation of skeletal
myoblasts to form myotubes [7]. There are four types of myosin heavy-chain (MyHC) isoforms in
skeletal muscles, including type I, IIa, IIx, and IIb. These isoforms are encoded by MyHC 7, MyHC 2,
MyHC 1, and MyHC 4 genes, respectively. Extensive research shows that different MyHC isoforms
have considerable effects on meat quality. Type I muscle fibers are thinner, and a high type I muscle
fibers ratio is beneficial for improving meat tenderness [8]. Furthermore, other research also found that
muscle with a higher type I muscle fiber ratio contained more intramuscular fat. The cross-sectional
region of type II muscle fibers is also greater, and an elevated type II fiber ratio can lead to increases in
muscle mass and animal weight [9].
MicroRNA is an endogenous, small non-coding RNA of ~22 nucleotides, which negatively
modulates gene expression levels by repressing translation and degradation of mRNA through
binding to 3’-UTR (3’-untranslated region) [10,11]. Emerging evidence has indicated that a number
of miRNAs can play vital roles during muscle development. For instance, miR-1, -133, and -206
have been recognized as muscle-specific miRNAs that modulate the function of skeletal muscles.
miR-1 and -206 modulate the satellite cell MD of bovine skeletal muscles by downregulating histone
deacetylase 4 (HDAC4) and paired box 7 (Pax7) expression [12]. According to the findings of miRNA
microarray and sequencing analysis, miR-1, −133 and −206 are remarkably upregulated during the
MD of bovine satellite cells [13,14]. Moreover, non-muscle-specific miRNAs can also regulate the
development of bovine skeletal muscles. In Qinchuan cattle, miR-101-1 is enriched in skeletal muscles,
and negatively regulates the differentiation of C2C12 cells [15]. In addition, miR-27b plays prominent
roles in the development and hypertrophy of bovine skeletal muscles [16]. In bovine myoblast
cells, miR-483 suppresses bovine myoblast cell growth and differentiation by negatively regulating
IGF1/PI3K/AKT pathway [17]. Some research showed that miR-23a suppressed the translation of
MuRF1 and MAFbx/atrogin-1 in a 3’-UTR-dependent fashion, and its forced expression in myofibers and
myotubes could prevent muscle atrophy [18]. In addition to that, miRNA-23a has been reported as a
critical regulator in colorectal cancer [19,20], lung cancer [21], pancreatic cancer [22], gastric cancer [23]
and hepatocellular carcinoma [24]. Our previous work also found that miR-23a was highly upregulated
during MD. Nevertheless, the impact of miR-23a on the MD of fetal bovine skeletal muscles has yet to
be determined.
MDFIC (MyoD family inhibitor domain containing) belongs to a small family of proteins
encompassing the cysteine-rich C-terminal domain [25,26]. Whilst, MyoD family inhibitor isoform
1 (MDFI, or named as I-mf or I-mfa) is another member of this family. The cysteine-rich C-terminal
domain of MDFIC contains 81 amino acids, which is 77% identical to that of MDFI. Approximately 26
and 24 cysteine residues are found in the C-terminal domains of MDFI and MDFIC, respectively. MDFI
restricts the transactivation functions of MyoD family members and prevents MD through binding
the basic helix-loop-helix (bHLH) domain of MyoD with cysteine-rich domain [27]. MDFI regulates
myogenesis by preventing DNA binding and nuclear localization of MyoD and bHLH proteins [28].
Although MDFIC shares relatively high identity with MDFI based on their amino acid sequences, the
functional role of MDFIC in myogenesis has not been addressed. A genome-wide association study on
pig has identified MDFIC as a candidate gene for determining piglet birth weight [29].
Hence, the current research aimed to identify the roles of bta-miR-23a in the differentiation of fetal
bovine myogenic cells, and its relationship with MDFIC. The findings demonstrated that bta-miR-23a
could promote myoblast differentiation via targeting MDFIC. Overall, this study provides new evidence
supporting the potential application of bta-miR-23a for preventing muscle atrophy.
2. Materials and Methods
2.1. Animal Ethics Statement
The experiment was carried out in strict accordance with the guidelines of the Regulations for
the Administration of Affairs Concerning Experimental Animals (Ministry of Science and Technology,
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China). The ethical approval was obtained from the Institutional Animal Ethics Committee, Chinese
Academy of Agricultural Sciences, China (No. IAS2019-48). Pregnant cattle were raised by the Aokesi
Agricultural Technology Co., Ltd. (Inner Mongolia, China). Every effort was made to reduce the
suffering of pregnant cattle.
2.2. Cell Culture and Treatment
bPCs were enzymatically isolated from the bovine fetus-derived longissimus dorsi tissues at
90–120 days according to previously reported method [30]. Longissimus dorsi was cut into smaller
pieces with scissors, and then digested with 0.1% type-IV collagenase (Sigma-Aldrich, St. Louis,
MO, USA) at 37 ◦C. Digestions were terminated by low-glucose DMEM (Gibco, Grand Island, NY,
USA) containing 10% fetal bovine serum (FBS; Gibco) after 1 hour. After filtering through a 40-µm
nylon mesh, the filtered cells were collected through centrifugation, and then resuspended in ice-cold
phosphate-buffered saline (PBS) buffer with 0.5% bovine serum albumin (BSA) and 2 mM EDTA. The
cells were then pretreated with anti-platelet-derived growth factor receptor α (PDGFRα) antibody
for 30 m at 4 ◦C. Washing and resuspending with PBS first and incubating with Anti-Rabbit IgG
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 minutes at 4 ◦C. After harvesting and
resuspending in buffer, the cells were subjected to magnetic separation with the Mini-MACS system
(Miltenyi Biotec). The obtained cells were then cultured in DMEM containing 10% FBS, followed by
incubation at 37 ◦C (5% CO2 atmosphere). Upon reaching 70–80% confluency, the cells were detached
using trypsin-EDTA (0.25%; Gibco) and subjected to passaging. When achieving 100% confluency [day
0 (D0)], the cells were differentiated to day 2 (D2), day 3(D3), and day 5 (D5) in DMEM containing 5%
horse serum (Gibco).
HEK293 (human embryonic kidney 293) cells were cultured in DMEM medium containiing 10%
FBS, 100 U/mL penicillin and 100 µg/mL streptomycin, followed by incubation at 37 ◦C (5% CO2
atmosphere).
2.3. RNA Extration and Real-Time PCR Assay
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was utilized to isolate total RNA from the
culturing cells. The yield and quality of RNA were evaluated by an Implen NanoPhotometer N50
(Munich, Germany) and 1% agarose gel electrophoresis, respectively. The results showed three clear
rRNA bands of 28S, 18S, and 5S. The ratio of the optical densities measured at 260 and 280 nm were
>1.9 for all RNA samples. The conversion of 500 ng total RNA to cDNA was initiated with PrimeScript
RT Master Mix (TaKaRa Bio, Kusatsu, Japan), while the reverse transcription reaction for miRNA was
conducted with miRcute miRNA First-Stand cDNA Synthesis Kit (TIANGEN, Beijing, China). The
real-time PCR reactions were carried out in triplicate on a QuantStudio™ 7 Flex RT-PCR System using
KAPA SYBR® FAST qPCR Kit (KAPABiosystems, Wilmington, MA, USA) and miRcute miRNA qPCR
Kit (TIANGEN). PCR primers for amplification of mRNA and miRNA-specific add the poly(A)-tail
primers were designed by Primer Premier 5.0 and synthesized by ShengGong. All experiments were
conducted as per the manufacturer’s recommended protocols. The primer sequences for mRNA and
miRNA detection are listed in Table 1.
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Table 1. Sequences designed for real-time PCR.
Name Primer Sequence (5’–3’) Annealing Temperature Accession Number
Myogenin (MyoG) F: CAAATCCACTCCCTGAAA 60 ◦C NM_001111325.1R: GCATAGGAAGAGATGAACA
Myosin heavy chain 1 (MyHC1) F: GGGAAACTGGCTTCTGCTGAT 60 ◦C NM_174117.1R: TGGGTTGGTGGTGATTAGGAG
Myosin heavy chain 2 (MyHC2) F: GTCAAAGGGACTATCCAGAGCAG 60 ◦C NM_001166227.1R: AGAAGAGGCCCGAGTAGGTGT
Myosin heavy chain 4 (MyHC4) F: CTCCTAATCACCACCAACCCATA 60 ◦C XM_002695806.5R: TGTCAGCAACTTCAGTGCCATC
Myosin heavy chain 7 (MyHC7) F: AAGACAGTGACCGTGAAGGAGG 60 ◦C NM_174727.1R: GGTTGATGGTGACGCAGAAGA
MyoD family inhibitor domain
containing (MDFIC)
F: TGAGGAGGAAATAAGCAAGATAA
60 ◦C NM_001101102.1R: CAGGATACAGTGGACACAGCAGT
bta-miR-23a F: ATCACATTGCCAGGGATTTCC 65 ◦C NR_031347.1
18s
F: GTAACCCGTTGAACCCCATT
60 ◦C NM_001025002.1R: CCATCCAATCGGTAGTAGCG
U6 F: GCTTCGGCAGCACATATACTAAAAT 65 ◦C NM_001075477.2
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2.4. Immunofluorescence Assay
First, the cells in 12-well plate were fixed in 4% paraformaldehyde for 15 minutes and rinsed
3 times for 5 minutes each in PBS. Then, the cells were permeabilized with 0.1% Triton X-100 for
10 minutes, followed by blocking with 1% BSA (Beyotime, Shanghai, China) for 30 minutes. Next,
the cells were incubated with anti-MyHC antibody (1:100; Developmental Studies Hybridoma Bank
[DSHB], Iowa City, IA, USA) at 4 ◦C overnight, and then with FITC-labeled Goat Anti-Mouse IgG (H +
L; 1:1000; Beyotime) at room temperature for 1 hour. After DAPI (Sigma-Aldrich) staining for 5 minutes,
the cell nuclei were examined using a TCS SP8 confocal microscope (Leica, Wetzlar, Germany).
2.5. Western Blotting
Total protein was isolated using the proteinase inhibitor-containing lysis buffer. Equivalent
amounts of protein were separated on a 4–12% SurePAGE gel (GenScript, Nanjing, China). After
electrophoresis, the separated proteins were placed onto a nitrocellulose membrane (Pall, Mexico),
and then inhibited with 5% (w/v) skimmed milk. The blocked membrane was incubated overnight at
4◦C with MDFIC (1:500; Biorbyt, Cambridge, UK), MyoG (1:1000; Santa Cruz, CA, USA), MyHC (1:50;
DSHB, USA) or β-tubulin (1:2000; Proteintech, Chicago, IL, USA). After rinsing 3 times in Tris-buffered
saline/Tween, the membranes were incubated with the corresponding HRP-labeled Goat Anti-Rabbit
IgG (1:1000; Beyotime) or HRP-labeled Goat Anti-Mouse IgG (1:1000; Beyotime) for 1 hour at room
temperature. The protein blots were visualized using the Enhanced Chemiluminescent Reagent
(Beyotime).
2.6. RNA Oligonucleotides, Plasmids Construction and Cell Transfection
The design and synthesis of bta-miR-23a mimic, mimic negative control (NC), small interfering
RNAs (siRNAs) for MDFIC knockdown and non-targeting siRNA NC were performed by RiboBio
(Guangzhou, China). The sequence of si-MDFIC was GAATCGAAGACTTTCAGCA. The 3’-UTR
region of MDFIC encompassing bta-miR-23a binding site was amplified and cloned into the XhoI/NotI
restriction sites of psi-CHECK2 vectors (Promega, Madison, WI, USA). Then, site-directed mutagenesis
was carried out using the Fast Site-Directed Mutagenesis Kit (TIANGEN).
To obtain the MDFIC overexpression plasmid, MDFIC open reading frame sequence was amplified
and cloned into pBI-CMV3 vector (Clontech, Mountain View, CA, USA) using ClonExpress MultiS One
Step Cloning Kit (Vazyme, Nanjing, China). MEF2C promoter sequence was taken out and cloned into
pGL3-basic vector by using ClonExpress MultiS One Step Cloning Kit (Vazyme). The primer sequences
used for plasmid construction and mutagenesis are listed in Table 2.
Cell transfection was conducted with Lipofectamine RNAiMAX reagent (Invitrogen), along with
bta-miR-23a mimic, NC, si-MDFIC and si-NC. Plasmid transfection was carried out with Lipofectamine
3000 (Invitrogen). All assays were conducted as per the manufacturer’s protocols.
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Table 2. Primer sequences designed for vector construction.
Name Primer Sequence (5’–3’) Annealing Temperature Accession Number
Psi-CHECK-MDFIC-W
F: ACTCTCGAGACTTTTCCTTTGTTGTCTATTC
60 ◦C NM_001101102.1R: ATAGCGGCCGCAGAGACCAAATCTGTAACTGTA
Psi-CHECK-MDFIC-Mut
F: AAAACAAAAGTAGCAAATATTTTCCATATG
60 ◦C NM_001101102.1R: CATATGGAAAATATTTGCTACTTTTGTTTT
pBI-CMV3 F: TCCTTCCTAAATCTCCAGAGGATCATAATCAGCCATAC 68 ◦CR: GATGATGATGATCGTCGACAAGCTTATCGATGC
MDFIC
F: TGTCGACGATCATCATCATCATCATCACATGTCCGGCGCGGGCGAAG
60 ◦C NM_001101102.1R: CTCTGGAGATTTAGGAAGGAAAACAAATCCCGCAGCACTCCATGC
pGL3-basic F: GGGCTCGAGATCTGCGATCTAAGTAAG 60 ◦CR: GGGCTAGCACGCGTAAGAGC
MEF2C
F: TCTTACGCGTGCTAGCCCTCACTTAGTATTAAAAATAGTTTGATTTTAAAAGTA
GAAAGGTCATATATGAAAAACATAATAAAGTCCAGGTAAAGAAATACCTGATAG 68 ◦C NM_001046113.1
R: AGATCGCAGATCTCGAGCCCTCTATGAAGACCCAGGCTTTCCCCCCTTG
Genes 2020, 11, 1232 7 of 17
2.7. Bioinformatic Analyses
TargetScanHuman 7.2 (http://www.targetscan.org/vert_72/) was employed for the prediction
of the target genes of bta-miR-23a. The predicted target genes with a context ++ score lower than
−0.3 were selected for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analyses were performed using the web-based DAVID bioinformatics resources
6.8 (https://david.ncifcrf.gov/home.jsp) and KOBAS 3.0 (http://kobas.cbi.pku.edu.cn/kobas3). All GO
terms and KEGG pathways with p-value below 0.05 and a minimum of 5 genes were chosen for
subsequent analyses.
2.8. Dual-Luciferase Reporter Assay
For luciferase detection, the HEK293 cell line was co-transfected with bta-miR-23a mimic or
NC and the wild-type or mutant plasmid in a 96-well plate using the Lipofectamine 3000 reagent
(Invitrogen). PDGFRα− bovine progenitor cells seeded in a 48-well plate and co-transfected with plasmid
of MEF2C promoter sequence with OV-MDFIC or si-MDFIC. After transfection for 48 h, the activities
of luciferase reporter (LR) were evaluated using a Dual-LR Assay System (Promega).
2.9. Statistical Analysis
The comparative (2-ddCt) method was used to present relative mRNA expression level. The
protein level was normalized to β-tubulin. Differentiation index was the percentage of nuclei in
MyHC–positive cells. The relative luciferase activity was monitored by renilla/firefly. The results of
the qPCR, differentiation index and luciferase reporter assays from the cell culture experiments are
presented as independent biological replicates, while the tissue qPCR analyses were analyzed using
three individual biological replicates. The data were plotted by GraphPad Prism ver. 6.0 (GraphPad
Software Inc., San Diego, CA, USA) and represented as the mean (± standard deviation (SD)). The
difference was considered as statistically significant when the p-value < 0.05 (*) or p-value < 0.01 (**)
3. Results
3.1. bta-miR-23a Expression Profile and Its Targets Analysis
In our previous work [31], we observed that bta-miR-23a was highly upregulated during MD.
The expression levels of bta-miR-23a were then detected in different tissues, such as heart, kidney,
leg muscle, liver, longissimus dorsi, lung, small intestine, spleen and stomach tissues derived from
fetal bovine, and it was found that bta-miR-23a had ubiquitous expression patterns in different tissue
types (Figure 1A). GO term enrichment was further conducted on bta-miR-23a target genes, and the
results demonstrated that bta-miR-23a was involved in muscle contraction, myofibril, myosin filament,
growth factor activity and nucleus (Figure 1B). Moreover, KEGG enrichment analysis demonstrated
that bta-miR-23a might be related to tight junction, focal adhesion, glycosphingolipid biosynthesis,
p53 signaling pathway, and the regulation of actin cytoskeleton (Figure 1C). Altogether, these data
imply that bta-miR-23a is a potential regulator in myogenesis.
Genes 2020, 11, 1232 8 of 17
Genes 2020, 11, x FOR PEER REVIEW 8 of 17 
 
 
Figure 1. bta-miR-23a expression profile and its targets analysis. (A) Tissue expression of bta-miR-23a examined 
by qPCR in fetal tissues. The fold change of bta-miR-23a was relative to bta-miR-23a expression of longissimus 
dorsi. (B) GO term enrichment of target genes for bta-miR-23a. (C) KEGG pathway analysis of target genes for 
bta-miR-23a. Results are representative of the mean (± SD) of three independent analyses.  
3.2. bta-miR-23a Is Upregulated During MD of PDGFRα− bPCs 
To explore the potential role of bta-miR-23a, PDGFRα− bPCs were isolated from fetal bovine skeletal 
muscles. It was observed that PDGFRα− bPCs could form myotubes after 2 days of myogenic induction 
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was found that the expression levels of MyHC-1, -2, and -4 were upregulated during MD, while 
MyHC-7 expression level was increased during first two days and then decreased afterwards (Figure 
2D). Besides, the expression trend of bta-miR-23a was shown to be increased during MD (Figure 2E). 
These results suggest that our in vitro MD model is reliable for studying the differentiation of PDGFRα− 
bPCs in fetal bovine skeletal muscle. 
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3.2. bta-miR-23a Is Upregulated During MD of PDGFRα− bPCs
To explore the potential role of bta-miR-23a, PDGFRα− bPCs were isolated from fetal bovine skeletal
muscles. It was observed that PDGFRα− bPCs could form myotubes after 2 days of myogenic induction
(Figure 2A,B). During D, MyoG expression was downregulated, hile MyHC expression was
increased (Figure 2C). Moreover, the expression of four MyHC genes was evaluated during MD. It was
found that the expression levels of MyHC-1, -2, and -4 were upregulated during MD, hile MyHC-7
expression level was increased uring first two days and then decrease afterwards (Figure 2D).
Besid s, the expression trend of bta-miR-23a was shown to be increased during MD (Figure 2E). These
results suggest that our in vitro MD model is reliable for studying the differentiation of PDGFRα− bPCs
in fetal bovine skeletal muscle.
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and 5 (Figure 3B). Similarly, bta-miR-23a overexpression increased the protein levels of MyoG and 
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promote the MD of PDGFRα− bPCs. 
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(A) Morphological features of DGFRα− bPCs at Day 0 (D0), 2 (D2), 3 (D3) and 5 (D5) after MD. Scale bar
represents 100 µm. (B) MyHC positive cells (green) at D0, D2, D3 and D5 after MD were examined by
fluorescence microscopy. Scale bar represents 100 µm. The protein (C) and mRNA (D) levels of MyoG
and MyHC. β-tubulin was used as the reference gene. (E) Relative expression of bta-miR-23a at D0, D2,
D3 and D5 after MD. Results are representative of the mean (± SD) of three independent analyses.
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higher co are to group (p < . after tr sf ti ,
Further, transfection of bta-miR-23a mimic or NC into he c lls was c rried out at D y 0 after MD. The
mRNA levels of MyHC1, MyHC2, MyHC4, and MyHC7 were noticeably upreg lat d on Day 2 and 5
(Figure 3B). Similarly, bt -miR-23a overexpression increased the protein levels of MyoG and MyHC
at Day 5 after MD (Figure 3C). Based on th immunofluorescence staining of myosin heavy chain, a
high number of cells underwent diff entiation and formed myotubes in imic group co pared to
NC group on Day 2 and 5 (Figure 3D,E). Taken together, bta-miR-23a is shown to promote the MD of
PDGFRα− bPCs.
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Figure 3. bta-miR-23a promoted MD of PDGFRα− bPCs. (A) The mRNA levels of bta-miR-23a in PDGFRα−
bPCs after 48-h transfection with bta-miR-23a mimics or NC mimics. (B) The mRNA expression of
MyoG and MyHCs in PDGFRα− bPCs at D2 and D5 after MD. (C) The protein levels of MyoG and MyHC
in PDGFRα− bPCs at 96 h after MD. β-tubulin was used as the reference gene. (D) MyHC (green) positive
cells at D2 and D5 after MD. Scale bar represents 100 µm. (E) Differentiation index of myoblast after
induction for D2 and D5. Results are representative of the mean (± SD) of three independent analyses.
** p < 0.01.
3.4. MDFIC Is A Promising Target Gene of bta-miR-23a
To elucidate the underlying mechanisms of bta-miR-23a-regulated gene expression, its target
genes were predicated using the TargetScan databases. The findings indicated that MDFIC could
be a promising target of bta-miR-23a (Figure 4A,B). To verify whether MDFIC is the direct target
gene of bta-miR-23a, 2 LR plasmids consisting of either the wild-type or mutant 3′ -UTR of MDFIC
gene were constructed (Figure 4A). Co-transfection of bta-miR-23a mimic or NC into HEK293T cells
was carried out. Notably, bta-miR-23a markedly decreased the activity of wild-type MDFIC LR in
comparison with those of negative control, but no significant changes were noted for the mutant LR
(Figure 4C). These findings indicate that bta-miR-23a can indeed directly target the 3′-UTR of MDFIC.
Moreover, we detected the expression of MDFIC during MD (Figure 4D). To examine the validity
of the putative target, bta-miR-23a mimic or NC was transfected into PDGFRα− bPCs. RT-qPCR data
revealed that the transcriptional levels of MDFIC were not obviously different between the mimic and
NC groups (Figure 4E). Interestingly, Western blot analysis indicated that the translational levels of
MDFIC were remarkably downregulated by bta-miR-23a mimic compared to NC group (Figure 4F).
Thus, we concluded that bta-miR-23a can directly target the 3’-UTR of MDFIC to suppress its mRNA
translation in PDGFRα− bPCs.
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3.5. Knockdown of MDFIC Promotes MD
To explore the roles of MDFIC during MD, PDGFRα− bPCs were transfected with siRNA against
MDFIC or NC. siRNA significantly diminished MDFIC mRNA and protein expression compared to NC
group (Figure 5A). The transcriptional and translational levels of MyoG and MyHC were obviously
higher in siRNA group than those in NC group at Day 5 after MD (Figure 5B,C). Immunofluorescence
staining revealed that the knockdown of MDFIC notably enhanced the process of MD (Figure 5D). Taken
altogether, our findings indicate that the inhibition of MDFIC can promote MD and myogenesis-specific
gene expression.
3.6. Overexpression of MDFIC Rescues the bta-miR-23a-Induced Effects
To further determine the regulation effect between bta-miR-23a and MDFIC, we performed rescue
experiments in myoblast differentiation. The mRNA level of MDFIC was significantly upregulated
after MDFIC overexpression (Figure 6A). Meanwhile, the results showed that overexpression of
MDFIC weakened the bta-miR-23a-induced effects, thus reducing the formation of myotubes, mRNA
and protein levels of MyHC1, MyHC2, MyHC4, MyHC7 and MyoG (Figure 6B,C). All these
results demonstrated that overexpression of MDFIC could attenuate the bta-miR-23a-induced effects
during MD.
Genes 2020, 11, 1232 12 of 17
Genes 2020, 11, x FOR PEER REVIEW 12 of 17 
 
 
Figure 5. Knockdown of MDFIC promotes the MD of PDGFRα− bPCs. (A) The mRNA and protein expression level 
of MDFIC in PDGFRα− bPCs transfected with si-MDFIC or si-NC. β-tubulin was used as the reference gene. The 
protein (B) and mRNA (C) expression levels of MyoG and MHC in PDGFRα− bPCs transfected with si-MDFIC or 
si-NC at D5 after MD. β-tubulin was used as the reference gene. (D) MyHC positive cells (green) at D5 of MD 
after si-MDFIC or si-NC transfection. Scale bar represents 100 μm. Differentiation index of myoblast after 
induction for D5. Results are representative of the mean (± SD) of three independent analyses. ** p < 0.01. 
3.6. Overexpression of MDFIC Rescues the bta-miR-23a-Induced Effects 
To further determine the regulation effect between bta-miR-23a and MDFIC, we performed 
rescue experiments in myoblast differentiation. The mRNA level of MDFIC was significantly 
upregulated after MDFIC overexpression (Figure 6A). Meanwhile, the results showed that 
overexpression of MDFIC weakened the bta-miR-23a-induced effects, thus reducing the formation of 
myotubes, mRNA and protein levels of MyHC1, MyHC2, MyHC4, MyHC7 and MyoG (Figure 6B,C). 
All these results demonstrated that overexpression of MDFIC could attenuate the bta-miR-23a-
induced effects during MD. 
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Figure 6. Overexpression of MDFIC rescues the miR-23a-induced effects. (A) The mRNA levels of
MDFIC in PDGFRα− bPCs transfected with mimic NC, miR-23a mimic or miR-23a mimic+MDFIC. (B)
MyHC (red) positive cells of MD after transfection with mimic NC, miR-23a mimic or miR-23a mimic +
MDFIC. Scale bar represents 100 µm. Differentiation index of myoblast after transfection with mimic
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NC, miR-23a mimic or miR-23a mimic + MDFIC. (C) The protein and mRNA expression levels of MyHC
and MyoG in PDGFRα− bPCs transfected with mimic NC, miR-23a mimic or miR-23a mimic+MDFIC.
β-tubulin was used as the reference gene. Results are representative of the mean (± SD) of three
independent analyses. * p < 0.05, ** p < 0.01.
3.7. MDFIC Regulate the Transcription Activity of MEF2C
To understand the relationship between MDFIC and MyoG, we cloned the promoter region of
MEF2C, a known target gene of MyoG [32], into pGL3-Basic vector. The MEF2C promoter containing
vector was co-transfected with OV-MDFIC or si-MDFIC with TK-Renilla plasmid, and the results
showed that OV-MDFIC reduced the LR activity while si-MDFIC increased the LR activity (Figure 7A,B).
These findings suggest that MDFIC may function through the interaction between MyoG transcription
factor and MEF2C the promoter.
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4. Discussion
In the present work, we reveal a role for bta-miR-23a during MD of PDGFRα− bPCs. Our results
indicated that bta-miR-23a controlled myoblast differentiation via targeting MDFIC. In addition,
MDFIC regulated the transcription activity of MEF2C by modulating MyoG expression (Figure 8).
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It has been demonstrated that miR-23a can modulate gene expression at the post-transcriptional
level, and is involved in a broad scope of cellular processes, including cell proliferation, apoptosis,
differentiation and metabolism [33–35]. Notably, miR-23a is responsible for the differentiation of stem
cells. miR-23a is highly upregulated in mouse embryonic stem cells (mESC) to suppress differentiation
toward the endoderm and ectoderm lineages, and is downregulated during the differentiation
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state [36]. miR-23a also maintains the balance between adipogenesis and osteogenesis in bone
marrow mesenchymal stem cells [37], and plays a key factor in osteogenesis by targeting RUNX2 and
TRPS1 [38,39]. In addition, miR-23a contributes to the early phases of neural differentiation by targeting
cyclin D1 and Musashi1 [40,41]. Our previous works have demonstrated that bta-miR-23a can regulate
the early commitment of intramuscular adipogenic differentiation by targeting ZNF423 [30]. Moreover,
previous studies have presented evidence that miR-23a plays crucial roles in muscle development
and performance. Delphinidin intake can induce miR-23a expression to attenuate disuse muscle
atrophy [42]. Besides, miR-23a is involved in cardiac hypertrophy via activation of muscle-specific
ring finger protein 1 [43]. Furthermore, the overexpression of miR-23a and -23b have been found in the
initial stages of C2C12 differentiation, and thus promote MD through suppressing TrxR1 expression [44].
However, in one study, MD can be inhibited by miR-23a via downregulation of fast MHC isoforms
using mice model and mice derived cells [45]. In this study, our results indicated that bta-miR-23a
could promote MD by suppressing MDFIC, which acted as an inhibitor of MD. The reason for this
inconsistency may be explained by the different materials or the different differentiation stages focused.
Here, the animal material was bovine fetus and its primary PDGFRα− bPCs. Therefore, we proposed a
new mechanism for the roles of bta-miR-23a during MD.
The inhibitor of MyoD family (I-mfa) is a transcription factor encoded by MDFI, which suppresses
the transactivation activities of MyoD family and inhibits skeletal myogenesis [27]. In this research,
interfering MDFIC increased the transcriptional and translational levels of MyoG and MyHCs, thereby
promoting the MD of PDGFRα− bPCs. Meanwhile, our rescue experiments further verified that MDFIC
overexpression could reverse the inducive effects of miR-23a during MD. Some studies have suggested
that I-mfa domain can target a group of bHLH proteins and repress Wnt signal transduction [46].
Moreover, I-mfa has been reported to suppress myogenesis by inhibiting lymphoid enhancer factor-1/T
cell factor (LEF-1/TCF), and such inhibition can be alleviated by canonical Wnt signaling through
elevating β-catenin levels [47]. Despite this, MDFIC and MDFI are belonging to the same family, and
the effects of MDFIC on MD has not yet been experimentally clarified. Here, we provided a new
insight to understand that MEF2C might be a key gene for the interaction between MDFIC and MyoG
during MD. Taken together, all these experimental results support a conclusion that MDFIC is involved
in myogenesis.
In conclusion, our study reveals that bta-miR-23a enhances the MD of PDGFRα− bPCs by directly
targeting MDFIC. In addition, MDFIC can regulate MEF2C transcription activity by regulating MyoG.
These data expand our mechanistic understanding of myogenesis and muscle development in which
miRNAs play an important role.
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